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Mounting evidence suggests that microRNA (miR) dysregulation contributes to neurodegenerative
disorders including Parkinson’s disease (PD). MiR-34b and miR-34c have been previously shown
to be down-regulated in the brains of patients with PD. Here, we demonstrate that miR-34b and
miR-34c repress the expression of a-synuclein (a-syn), a key protein in PD pathogenesis. Inhibition
of miR-34b and miR-34c expression in human dopaminergic SH-SY5Y cells increased a-syn levels
and stimulated aggregate formation. Additionally, a single nucleotide polymorphism (SNP) in the
30-UTR of a-syn was found to lower the miR-34b-mediated repression of the protein. Our
results suggest that down-regulation of miR-34b and miR-34c in the brain, as well as an SNP in
the 30-UTR of a-syn can increase a-syn expression, possibly contributing to PD pathogenesis.
 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Parkinson’s disease (PD) is the second most common neurode-
generative disorder affecting 1–2% of the population over the age
of 65. PD is characterized by the presence of cytoplasmic inclusions
in the surviving neurons called Lewy bodies (LBs) and Lewy neu-
rites, which consist mainly of a-synuclein (a-syn) [1,2]. Point
mutations in the a-syn gene are linked to dominantly inherited
PD [2], and individuals with multiplication of this gene locus
develop PD with an early-onset age and phenotypic severity that
are consistent with a gene dosage effect [3,4]. Additionally, a poly-
morphism in the a-syn gene promoter region results in enhanced
transcription and is associated with increased risk of PD [5]. Even
in sporadic PD patients, a-syn mRNA has been found to be signif-
icantly upregulated as assessed by quantitative RT-PCR using a
pool of individual dopaminergic neurons isolated by UV-laser
microdissection microscopy from postmortem brains [6,7]. There-
fore, increased expression of a-syn appears to be a key factor
underlying the pathogenesis of PD. Here, we provide experimental
evidence to suggest a possible mechanism leading to increased
a-syn expression through dysregulation of a-syn targeting microR-
NAs (miRs), miR-34b and miR-34c, in the brains of PD patients.miRs are small non-coding RNAs that regulate post-transcrip-
tional gene expression by binding to the 30-UTR of the mRNA. Dys-
regulation of miR expression and/or function has been associated
with several neurodegenerative diseases including PD [8–11]. Previ-
ously, miR-7 and miR-153 were reported to target and downregu-
late a-syn expression [12,13]. However, it is not known whether
these two miRs are altered in PD brains. Interestingly, miR-34b
(miR-34b-3p) andmiR-34c (miR-34c-5p) are reportedly downregu-
lated in the brain areas of PD patients including the amygdala, fron-
tal cortex, substantia nigra and cerebellum, suggesting their
possible mechanistic role in PD pathogenesis [14,15]. Reducing
the levels of miR-34b and miR-34c recapitulates several biochemi-
cal and cell biological alterations observed in PD brains including
oxidative stress, impaired mitochondrial function and decreased
viability of dopaminergic neuronal cells [14]. In the present study,
we show that miR-34b and miR-34c repress a-syn expression
through its 30-UTR, while inhibition of miR-34b and miR-34c ele-
vates a-syn level and leads to the formation of a-syn-containing
aggregates. We suggest that decreased expression of miR-34b and
miR-34c found in PD brains can result in elevated a-syn level and
aggregate formation, which might contribute to PD pathogenesis.2. Materials and methods
2.1. Materials
All pre-miRs and anti-miRs were purchased from Ambion.
Fig. 1. Inhibition of miR-34b and miR-34c increases a-syn expression. (A and B) SH-SY5Y cells were transfected with anti-miR-34b and anti-miR-34c for 48 h followed by
Western blot analysis using anti-a-syn antibody and b-actin antibody. Relative protein levels were normalized to b-actin and calculated based on band intensity using NIH
Image J Software. Anti-miR-SC denotes anti-miR-scrambled sequence. (C and D) Quantitative RT-PCR of a-syn mRNA levels in cells transfected as in panels (A and B). Values
are normalized to 18S rRNA. Data are shown as mean ± S.D. ⁄P < 0.05, ⁄⁄P < 0.01 and ⁄⁄⁄P < 0.001.
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The ﬁreﬂy luciferase reporter construct containing human a-
syn 30-UTR was previously described [12]. Mutations of the miR-
34b and miR-34c predicted target site in the a-syn 30-UTR were
created using the QuikChange site-directed mutagenesis kit
(Stratagene) with primers 50-GAAGTCTTCCATCAGCAGTCTTTGAA
GTATCTGTACCTG-30 and 50-CAGGTACAGATACTTCAAAGACTGCTGA
TGGAAGACTTC-30 for miR-34b site 1, 50-GTTGTTCAGAAGTTGT-
TAGTCTTTTGCTATCATATATTATAAG-30 and 50-CTTATAATATATGA-
TAGCAAAAGACTAACAACTTCTGAACAAC-30 for miR-34b site 2,
and 50-GAATTCCCTGAAGCAACAGACCCAGAAGTGTGTTTTGG-30 and
50-CCAAAACACACTTCTGGGTCTGTTGCTTCAGGGAATTC-30 for miR-
34c site. The minor allele sequence of SNP rs10024743 was intro-
duced in the a-syn 30-UTR reporter plasmid using primers 50-CAG-
CAGTGATTGAAGTATCTG-30 and 50-CAGATACTTCAATCACTGCTG-30.
2.3. Cell cultures and transfections
Human neuroblastoma cell line, SH-SY5Y, was purchased from
American Type Culture Collection. Cells were maintained in Dul-
becco’s Modiﬁed Eagle Medium (Invitrogen) supplemented with
10% fetal bovine serum (Invitrogen). Cells were transfected with
anti-miRs and pre-miRs at the concentration of 50 nM using Lipo-
fectamine RNAiMax (Invitrogen) for 48 h before harvest.
2.4. Reporter gene assay
Cells were cotransfected with luciferase reporter constructs and
internal control construct pSV-b-galactosidase in the absence or
presence of pre-miR-34b and pre-miR-34c. After cell lysis withGlo Lysis Buffer (Promega), luciferase activity was measured with
Steady-Glo Luciferase Assay System (Promega) using a Wallac
1420 Multilabel Counter (PerkinElmer). b-Galactosidase activity
was measured using chlorophenol red-b-D-galactopyranoside
(CPRG) (Roche) in a reaction buffer (60 mM Na2HPO4, 40 mM
NaH2PO4, 10 mM KCl, 1 mM MgSO4, 50 mM 2-mercaptoethanol,
pH 7.0) to normalize luciferase activity. Experiments were per-
formed in triplicates.
2.5. Western blot analysis
Cell lysates were analyzed by Western blotting as described
previously [12] using mouse monoclonal anti-a-syn antibody
SYN-1 (Invitrogen) and monoclonal b-actin antibody (Sigma). Band
densities were measured using National Institutes of Health (NIH)
Image J.
2.6. Quantitative real-time PCR
To quantify a-syn mRNA levels, total RNA was prepared from
SH-SY5Y cells using Trizol reagent (Invitrogen) according to man-
ufacturer’s instructions. Reverse Transcription was performed with
2 lg total RNA in 20 ll reaction. Real-time PCR was performed in
triplicates with SYBR Select Master Mix (Applied Biosystems) in
an Applied Biosystems 7500 Real-Time PCR System. PCR primer
sequences used were as follows: 18S rRNA (50-CGGCTACCACATC-
CAAGGAA-30 and 50-GCTGGAATTACCGCGGCT-30), a-syn (50-ACCAA
ACAGGGTGTGGCAGAAG-30 and 50-CTTGCTCTTTGGTCTTCTCAGCC-
30) and b-syn (50-AAGCAAGACCCGAGAAGGTGTG-30 and 50-ATT-
CCTCCCTCTTCACCAGTCC-30). Relative mRNA expression level was
calculated by the 2DDCt method.
Fig. 2. miR-34b and miR-34c target a-syn expression. Schematic representation of the two predicted binding sites (#1 and #2) for miR-34b (A) and one site for miR-34c (B) in
the 30-UTR of a-syn. Sites are conserved in human, chimpanzee and rhesus monkey. Quantitative RT-PCR analysis of a-syn mRNA levels was performed on SH-SY5Y cells
transfected with miR-34b (C) and miR-34c (D) for 48 h. Levels of a-syn mRNA are normalized to 18S rRNA. SH-SY5Y cells were transfected with pre-miR-34b (E) and pre-miR-
34c (F) for 48 h followed by Western blot analysis using anti-a-syn antibody. Band intensities are quantiﬁed and shown below the respective blots. Data are shown as
mean ± S.D. ⁄⁄P < 0.01 and ⁄⁄⁄P < 0.001.
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Cells were ﬁxed in 4% paraformaldehyde in PBS for 20 min,
washed with PBS three times, and permeabilized with 0.5% Triton
X-100 in PBS for 10 min. After washing with PBS again and block-
ing with 5% donkey serum for 20 min, cells were incubated with
anti-a-syn antibody (SYN-1) diluted in 1% donkey serum at room
temperature for 1 h and washed with PBS and incubated with
DyLight 488-conjugated anti-mouse IgG (Jackson immunore-
search) diluted in PBS containing 1% donkey serum for 1 h at room
temperature. For nuclear staining, cells were incubated with 1 lg/
ml 40,60-diamidino-2-phenylindole dihydrochloride (DAPI; Sigma–
Aldrich) in PBS for 1 min at room temperature. Cells were washedﬁve times with PBS and analyzed under a ﬂuorescence microscope
(Axiovert 200, Zeiss). For quantiﬁcation of aggregates, 6 micro-
scopic ﬁelds containing at least 100 cells per group were randomly
selected, and the average number of aggregates per 100 cells was
calculated.
2.8. Statistical analysis
All experiments were done in triplicates, and statistical signiﬁ-
cance between control and experimental values was determined
using Student’s t test (paired, two-tailed). All data are expressed
as means ± standard deviations (S.D.) or mean ± standard error
(S.E.M.) as described.
Fig. 3. miR-34b and miR-34c target a-syn 30UTR. SH-SY5Y cells were co-transfected
with pre-miR-34b (A) or pre-miR-34c (B) along with reporter constructs containing
control vector, a-syn 30UTR or its mutants (34b-M1, 34b-M2, 34b-M1/M2 and 34c-
M) and pSV-b-galactosidase. Luciferase activity was normalized against b-galacto-
sidase activity. Schematic representations of mutant a-syn 30-UTR reporter
constructs are shown below the respective graphs. Data are shown as mean ± S.D.
⁄⁄⁄P < 0.001.
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3.1. Inhibition of miR-34b or miR-34c increases a-syn expression
The effect of reduced levels of miR-34b and miR-34c in PD
patients was recapitulated in human dopaminergic SH-SY5Y cells
by utilizing anti-miRs, which are designed to speciﬁcally bind toand inhibit corresponding endogenous mature miRs. To examine
whether inhibiting these miRs leads to increased a-syn protein
level, lysates from cells transfected with anti-miR-34b or anti-
miR-34c were examined using Western blot analysis. Indeed,
inhibiting miR-34b (Fig. 1A) or miR-34c (Fig. 1B) signiﬁcantly
increased a-syn protein expression by 2.2-fold and 1.7-fold,
respectively. Also, quantitative real time PCR analysis revealed that
a-syn mRNA level was signiﬁcantly elevated by 1.5-fold (Fig. 1C
and D) upon inhibiting either of these miRs, suggesting the regula-
tion of a-syn mRNA by miR-34b and miR-34c in SH-SY5Y cells.
3.2. miR-34b and miR-34c reduce a-syn expression
By performing sequence alignment using TargetScan, we identi-
ﬁed potential miR-34b and miR-34c binding sites in the 30-UTR of
a-syn mRNA, which are conserved in humans, chimpanzee and
rhesus (Fig. 2A and B). Computational analysis using RNAhybrid
algorithm [16] predicted base pairing with two target sites for
miR-34b and one target site for miR-34c within the a-syn mRNA.
The minimal free energy is 14.3 kcal/mol for miR-34b site 1,
18.6 kcal/mol for miR-34b site 2, and 22.9 kcal/mol for miR-
34c site, suggesting favorable interactions between these miRs
and their respective sites. To examine the effect of miR-34b and
miR-34c on the expression of a-syn, SH-SY5Y cells were transfec-
ted with pre-miR-34b and pre-miR-34c followed by quantitative
real time PCR analysis. Overexpression of miR-34b or miR-34c
resulted in signiﬁcant reduction in a-syn mRNA expression
(Fig. 2C and D) and a-syn protein level (Fig. 2E, and F), suggesting
that miR-34b and miR-34c target a-syn mRNA. However, miR-34b
and miR-34c were unable to repress b-synuclein (b-syn) expres-
sion, a highly homologous protein to a-syn (Supplementary
Fig. 1). Rather, miR-34c increases b-syn expression up to 2.3-fold
through an unknown mechanism (Supplementary Fig. 1). Taken
together, we conclude that miR-34b and miR-34c repress a-syn
expression, but not b-syn expression. Further, comparison of
miR-34b and miR-34c to previously identiﬁed miRs that target a-
syn 30UTR, i.e., miR-7 and miR-153, revealed that all the tested
miRs downregulate a-syn protein level to a similar extent (Supple-
mentary Fig. 2).
3.3. Conﬁrmation of miR-34b and miR-34c target sites in the 30-UTR of
a-syn mRNA
To verify whether miR-34b and miR-34c directly target the 30-
UTR of a-syn mRNA, we utilized a plasmid construct expressing
full-length a-syn 30-UTR downstream of the ﬁreﬂy luciferase
reporter gene. Co-transfection of miR-34b or miR-34c along with
this reporter construct signiﬁcantly decreased luciferase activity,
but did not affect the control vector pGL3 devoid of the a-syn 30-
UTR (Fig. 3A and B), indicating that miR-34b and miR-34c work
through the 30-UTR of a-syn. To ensure that the predicted target
sites of miR-34b and miR-34c in the a-syn 30-UTR are functional,
these sites were mutated as shown in Fig. 3A and B. Compared with
54% repression of luciferase activity from the wild-type a-syn 30-
UTR construct upon co-transfection with pre-miR-34b, the a-syn
30-UTR construct mutated at the predicted miR-34b site 1 (34b-
M1) or site 2 (34b-M2) could be repressed by only 24% and 27%,
respectively, (Fig. 3A). Further, mutating both miR-34b binding
sites (34b-M1/M2) in the 30UTR completely abrogated its suppres-
sion (Fig. 3A). Similarly, miR-34c was able to repress the expres-
sion of the reporter gene by only 16% from the a-syn 30-UTR
construct containing 34c-M mutated site compared to 41% repres-
sion from the construct containing the predicted wild-type
sequence (Fig. 3B). These results indicate that the predicted
sequences are authentic binding sites for miR-34b and miR-34c.
Fig. 4. Inhibition of miR-34b or miR-34c increases a-syn aggregation. Representative pictures showing a-syn-containing aggregates upon transfection of SH-SY5Y cells with
anti-miR-SC (A), anti-miR-34b (B), anti-miR-34c (C) and combination of anti-miR-34b and anti-miR-34c (D) for 48 h. Aggregates are shown with red arrowheads. (D)
Quantiﬁcation of average number of a-syn aggregates for every 100 cells. Data are shown as mean ± S.E.M. ⁄⁄P < 0.01 and ⁄⁄⁄P < 0.001.
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As inhibition of miR-34b or miR-34c led to increased a-syn
expression (Fig. 1), we investigated whether transfection of anti-
miR-34b or anti-miR-34c could also lead to the formation of a-
syn-containing aggregates. To this end, SH-SY5Y cells were trans-
fected with anti-miR-34b, anti-miR-34c or both, and the formation
of aggregates were assessed by immunocytochemistry using anti-
a-syn antibody. As shown in Fig. 4, inhibiting either miR-34b or
miR-34c led to an increase in the formation of a-syn-containing
aggregates, and inhibition of both miRs led to further increase in
aggregate formation. Therefore, we suggest that reduced levels ofmiR-34b and miR-34c found in PD brains could signiﬁcantly
increase a-syn expression and the formation of a-syn-containing
aggregates in dopaminergic neurons.
3.5. A SNP in a-syn 30UTR makes resistant to miR-34b
We identiﬁed a polymorphic variation (rs10024743) in the 30-
UTR of human a-syn from the GenBank SNP database, although
its association with PD is not known. This particular variation lies
within the target site 1 of miR-34b. To examine the functional
impact of this SNP on the a-syn 30-UTR, base substitution at posi-
tion 548 was introduced from thymine (major allele) to guanine
Fig. 5. SNP rs10024743 reduces miR-34b-mediated a-syn repression. (A) A
schematic representation of the major and minor alleles of SNP rs10024743
present in a-syn 30-UTR. (B) SH-SY5Y cells were co-transfected with reporter
constructs containing a-syn 30-UTR or SNP rs10024743 along with miR-SC or miR-
34b or miR-34c for 48 h. Luciferase activity was normalized against b-galactosidase
activity. Data are shown as mean ± S.D. ⁄⁄⁄P < 0.001.
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struct. Co-transfection of the construct containing the major a-syn
30-UTR allele with pre-miR-34b decreased luciferase activity by
57% as expected, whereas this repression was only 25% for the
construct containing the minor allele of a-syn 30UTR (Fig. 5B). In
contrast, miR-34c repressed major and minor allele to a similar
extent (Fig. 5B). Therefore, we suggest that individuals harboring
the rs10024743 SNP could be resistant to miR-34b-mediated
repression of a-syn expression, and this could result in increased
a-syn expression and subsequent aggregate formation.
4. Discussion
Accumulating evidence suggests that alterations in miR expres-
sion in the brain is involved in the pathogenesis of PD [14,15,17–
20]. Minones-Moyano et al. initially reported the diminished
expression of miR-34b and miR-34c in the substantia nigra [14],
which was conﬁrmed by a recent report [15]. Inhibition of miR-
34b and miR-34c in differentiated SH-SY5Y neuroblastoma cells
led to loss of mitochondrial membrane potential and oxidative
stress, which are known biochemical abnormalities associated
with PD. In addition, both parkin and DJ-1 expression levels were
shown to be marginally decreased upon inhibiting the activity of
miR-34b and miR-34c. Considering that expression of target genes
is expected to increase upon inhibiting their respective miRs, it is
likely that miR-34b and miR-34c do not directly target parkin
and DJ-1. Consequently, identifying the physiological targets of
miR-34b and miR-34c is necessary to better understand the role
of these miRNAs in the pathogenesis of PD.
The present investigation provides a mechanistic correlation
between the decrease in miR-34b and miR-34c found in the brains
of PD patients and a-syn, a key protein in PD. In addition to accu-
mulation of a-syn as ﬁbrillar aggregates in Lewy bodies and Lewy
neurites in affected brain regions, the level of a-syn appears to be
critical in PD pathogenesis since multiplication of its gene locus
leads to autosomal dominant PD. Two miRs, miR-7 and miR-153,
have been shown to repress a-syn levels post-transcriptionally
by binding to the 30-UTR of the a-syn mRNA [12,13]. However,
alterations in the expression of these miRs have yet to be demon-
strated in PD. In this report, we show that miR-34b and miR-34ctarget the 30-UTR of a-syn mRNA, thus decreasing a-syn protein
levels to the similar extent as miR-7 and miR-153. Speciﬁcally,
miR-34b targets a-syn mRNA at two distinct sites, while miR-34c
targets at least one site, as ascertained by utilizing luciferase con-
struct with a-syn 30-UTR. The repression mediated by miR-34b was
completely rescued upon mutating its two binding site in the
30UTR of a-syn mRNA, conﬁrming the mechanism of action. How-
ever, lack of complete derepression after mutation of miR-34c
binding site in the a-syn 30-UTR suggests a possibility of weaker
binding of miR-34c to mutated site or presence of other target
sites. Further, inhibition of miR-34b and miR-34c leads to increase
in a-syn expression and the formation of a-syn-containing aggre-
gates. Combined with the observation that the level of miR-34b
and miR-34c are decreased in PD brains, we suggest that elevated
expression of a-syn due to loss of miR-34b and miR-34c might
contribute to the pathogenesis of PD.
In addition to the multiplication of a-syn locus as a cause of PD,
SNPs in the a-syn gene have also been associated with increased
risk of the disease [21–23]. Also, SNPs in miRNA target sites in
the 30-UTR of mRNA affect the interactions between miRNAs and
their targets, altering protein expression and potentially impacting
disease risk. For example, a signiﬁcant association has been
reported in PD with SNP (rs12720208 [C/T]) located in the 30-
UTR of FGF20 mRNA. This genetic variation lies within a predicted
binding region for miR-433 [24]. The risk allele impedes the bind-
ing of the mRNA with miR-433 and augments FGF20 expression.
Further, this variation seems to enhance the vulnerability to PD
through increased a-syn expression, which is mediated by
FGF20. However, other reports have failed to replicate an associa-
tion between SNPs of FGF20 and PD risk, or the connection
between the variation rs12720208 and a-syn protein levels
[25,26]. In the present study, we identiﬁed a polymorphic variation
(rs10024743) in the 30-UTR of human a-syn from the GenBank SNP
database, although its association with PD is not known. This par-
ticular variation lies in the potential target site of miR-34b. We
show that this polymorphism is associated with resistance to
miR-34b action and subsequently leads to increased a-syn protein
levels. It will be interesting to investigate if this genetic variation
(rs10024743) is associated with increased risk of PD.
In conclusion, our data suggest that the reduction in miR-34b
and miR-34c levels in PD patients’ brains could result in increased
a-syn levels and the formation of a-syn-containing aggregates. We
also demonstrate that a polymorphism in the miR-34b target
sequence of the a-syn 30-UTR that diminishes the repressive activ-
ity of this miR can lead to increased a-syn levels. Thus, dysregula-
tion of these miRs as well as sequence variations in their target
sequence might modulate disease risk.
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